IFN-α2 Antibody (5E683) is a mouse monoclonal IgG2a antibody that detects IFN-α2 in human samples through western blotting (WB). IFN-α2, a member of the type I interferon family, plays a crucial role in the immune response by mediating antiviral activity and modulating immune functions. This cytokine helps inhibit viral replication and enhances the activity of immune cells, such as natural killer cells and macrophages, contributing to the overall defense against infections and tumors. IFN-α2 is primarily secreted by virus-infected cells and acts on various target cells through the type I interferon receptor, a complex of multiple subunits that facilitates the signaling cascade necessary for the biological effects of interferons. Anti-IFN-α2 antibody (5E683) enables researchers to study how IFN-α2 induces the expression of numerous interferon-stimulated genes, underscoring its significance in both antiviral and antitumor immunity, making IFN-α2 a valuable target for therapeutic interventions in various diseases, including certain cancers and autoimmune disorders.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IFN-α2 Antibody (5E683) References:
- Sub-acute effects of interferon-alpha 2 on adrenocorticotrophic hormone, cortisol, growth hormone and prolactin in humans. | Müller, H., et al. 1992. Psychoneuroendocrinology. 17: 459-65. PMID: 1336606
- Interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man. | Müller, H., et al. 1991. Neuroendocrinology. 54: 499-503. PMID: 1660965
- siRNA high-throughput kinase library screen identifies protein kinase, DNA-activated catalytic polypeptide to play a role in MyD88-induced IFNA2 activation and IL-8 secretion. | Charlaftis, N., et al. 2012. Biotechnol Appl Biochem. 59: 6-14. PMID: 22332739
- Inhibition of human HT29 colon carcinoma growth in vitro and in vivo by swainsonine and human interferon-alpha 2. | Dennis, JW., et al. 1989. J Natl Cancer Inst. 81: 1028-33. PMID: 2499693
- Modulation of granulocyte oxidative response by recombinant interferon alpha 2 and gamma. | Kapp, A., et al. 1986. Arch Dermatol Res. 278: 274-6. PMID: 3090949
- Recombinant human interferon alpha-2 and juvenile chronic myelogenous leukemia: cell receptor binding, enzymatic induction, and growth suppression in vitro. | Estrov, Z., et al. 1987. Exp Hematol. 15: 127-32. PMID: 3102273
- Single high affinity binding of interferon alpha 2 to receptors on human lymphoblastoid cells: internalization and inactivation of receptors. | Faltynek, CR., et al. 1985. J Cell Physiol. 123: 459-66. PMID: 3157692
- Human recombinant interferon-alpha-2 in the treatment of patients with hairy cell leukemia. | Skotnicki, AB., et al. 1988. Cancer Detect Prev. 12: 511-22. PMID: 3180143
- Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy. | Millar, BC., et al. 1996. Br J Cancer. 73: 236-40. PMID: 8546912
- Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2. | Nolte, KU., et al. 1996. Eur J Immunol. 26: 2155-9. PMID: 8814261